GlassScriptPhysician profile
Laura E Mcgarry
NPI 1083065643
$6,454.40
in general payments reported to CMS, 2019-2025
34 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $12.37 · 2021: $2,385 · 2022: $1,485 · 2023: $1,526 · 2024: $755 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.25 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,339.62 | 2021-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $560.64 | 2022-2025 | Interstim |
| Urovant Sciences INC | $434.10 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $329.53 | 2023-2024 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $298.61 | 2021-2024 | Myrbetriq, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $234.51 | 2021-2024 | |
| Coloplast Corp | $202.02 | 2020-2023 | Speedicath |
| Olympus America INC. | $165.86 | 2023-2025 | Itind System |
| Boston Scientific Corporation | $160.97 | 2019-2022 | |
| Abbvie INC. | $160.13 | 2022-2023 | |
| Allergan, INC. | $149.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $148.35 | 2021-2023 | Keytruda, Lynparza |
| Progenics Pharmaceuticals, INC. | $146.72 | 2022-2023 | Pylarify |
| Dendreon Pharmaceuticals LLC | $101.26 | 2022-2023 | Provenge |
| Bluewind Medical | $98.11 | 2024 | Revi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $96.61 | 2022-2025 | Lynparza, Imfinzi |
| Novartis Pharmaceuticals Corporation | $83.41 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $82.81 | 2021-2023 | Aveed, Xiaflex |
| Urogen Pharma, INC. | $76.05 | 2022 | |
| Mission Pharmacal Company | $66.95 | 2022-2023 | Uribel |
| Tolmar, INC. | $59.11 | 2023 | |
| Medtronic USA, INC. | $56.20 | 2019 | |
| Amgen INC. | $54.32 | 2022-2023 | Xgeva |
| Myriad Genetic Laboratories, INC. | $54.16 | 2022-2023 | Prolaris |
| Teleflex LLC | $42.42 | 2022 | |
| Foundation Medicine, INC. | $40.37 | 2022-2023 | Foundationone Cdx |
| Myovant Sciences INC. | $34.66 | 2022 | |
| Hollister Incorporated | $33.99 | 2022-2023 | Vapro, Infyna Chic |
| Accord Healthcare, INC. | $32.09 | 2023-2024 | |
| Antares Pharma, INC. | $30.84 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Telix Pharmaceuticals | $28.40 | 2023 | Illuccix |
| Tolmar Pharmaceuticals, INC. | $24.19 | 2022 | |
| Clarus Therapeutics INC. | $15.86 | 2021 | |
| Pfizer INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Mcgarry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.